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Decreased phosphate reabsorption after renal transplantation:
Evidence for a mechanism independent of calcium and parathyroid
hormone. We studied a group of 73 transplant recipients who had
had stable renal function for more than 6 months after their
transplant surgery. Of these 73 patients, 23 had fasting plasma
phosphate concentrations less than 2.5 mg/dl (normal, 3 to 5 mgI
dl). The concentration of plasma phosphates was 2.1 0.1 mg/dl
in the hypophosphatemic transplant-recipient group compared
with 3.0 0.1 mg/dl in the total transplant-recipient population.
The hypophosphatemic patients had similar fractional phosphate
reabsorption when compared with the total transplant-recipient
population, and their renal phosphate threshold (Tm04IGFR)
was reduced from 3.0 0.1 mg/dl in the total population to 1.4
0.2 mg/dl. Although PTH levels correlated inversely with the
Tmp04IGFR in the total transplant-recipient group, the hypo-
phosphatemic patients appeared to exhibit lower renal phosphate
thresholds than did normophosphatemic transplant-recipients
with similar PTH levels. To further evaluate the relationship
between PTH and renal phosphate handling, we performed
calcium infusion and phosphate titration studies on 11 hypophos-
phatemic transplant-recipients. The data revealed that 5 of the II
patients with only mildly abnormal PTH levels failed to decrease
their rate of phosphate excretion, their phosphate clearances,
and their fractional excretion of phosphate during calcium infu-
sion. The 5 nonresponders to calcium infusion also exhibited
smaller increments in their plasma phosphate concentration and
TmQ4/GFR than did the 6 patients who responded to calcium
infusion with reductions in phosphate excretion rates. Before
calcium infusion, cyclic 3'5'-adenosine monophosphate excre-
tion rates were similar in both responders and nonresponders
and were decreased to the same degree by the calcium infusions.
These data indicate the presence of either a defect in phosphate
reabsorption that is independent of the action of PTH and
calcium or a heightened sensitivity to PTH with a decreased
suppressibility of response to PTH.
Diminution de Ia reabsorption de phosphate après transplanta-
tion rénale: Preuve de l'existence d'un mécanisme indépendant du
calcium et de l'hormone parathyroidienne. Dans un groupe de 73
receveurs de reins ayant une fonction rénale stable, 23 avaient
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une concentration plasmatique de phosphate a jeun inférieure a
2,5 mg/dl (normale, 3 a 5 mg/dl). Les phosphatémies étaient de
2,1 0,1 mg/dl dans le groupe hypophosphatémique et de 3,0
0,1 mgldl dans l'ensemble de Ia population des sujets trans-
plantés. Les sujets hypophosphatemiques avaient Ia méme réab-
sorption fractionnelle de phosphate que l'ensemble de la popula-
tion et leur seuil de phosphate (Tm04/GFR) était réduit de 3,0
0,1 mg/dl dans l'ensemble de Ia population a 1,4 0,2 mg/dl.
I3ien que les concentrations de PTH soient inversement corré-
lees avec le Tm04/GFR dans l'ensemble du groupe des trans-
plantds, les receveurs hypophosphatemiques paraissent avoir
des seuils rénaux de phosphate inférieurs a ceux des receveurs
normophosphatémiques pour des niveaux semblables de PTH.
Afin de mieux évaluer Ia relation entre PTH et comportement
renal du phosphate, 11 receveurs hypophosphatémiques ont subi
une perfusion de calcium et une titration de phosphate. Les
résultats montrent que 5 parmi II malades dont les valeurs de
PTH étaient seulement modérément dlevées n'ont pas diminuC
leur debit d'excrétion de phosphate, leur clearance de phosphate
et leur excretion fractionnelle de phosphate au cours de la
perfusion de calcium. Les 5 sujets qui n'ont pas répondu a Ia
perfusion de calcium avaient aussi des augmentations plus
faibles de Ia phosphatemie et de Tm04/GFR que celles des 6
malades qui réspondaient a Ia perfusion de calcium par une
diminution du debit d'excrétion du phosphate. Les valeurs
d'excrdtion du 35-cAMP étaient semblables dans les deux
groupes de sujets et étaient abaissées de Ia mCme facon par les
perfusions de calcium. Ces résultats indiquent l'existence dun
deficit de Ia réab sorption de phosphate indépendant de Ia PTH et
du calcium ou bien d'une augmentation de Ia sensibilité a Ia PTH
avec une diminution de Ia possibilitd de supprimer Ia réponse a Ia
PTH.
Patients who have received a renal transplant
from either living related or cadaveric donors fre-
quently develop hypophosphatemia [1—3], which is
often associated with hypercalcemia in the early
posttransplant period. The presence of high levels
of parathyroid hormone (PTH) in the early period
following reestablishment of renal function ade-
quately explains hypophosphatemia in this setting
I1]. But, often hypophosphatemia is observed also
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in the late posttransplant period even when renal
function is stable and creatinine clearance exceeds
70 mi/mm [2—31. These patients usually have re-
duced rates of renal phosphate reabsorption as
assessed by the fractional excretion of the filtered
phosphorus load or by the maximal reabsorptive
rates during phosphate infusion [2—31. Also, their
intestinal phosphate absorption has been found to
be disordered [41. Nevertheless, current evidence
suggests that phosphaturia is a key factor contribut-
ing to the hypophosphatemia observed in these
patients.
Of the potential factors controlling renal phos-
phate transport, PTH has been the one most often
implicated as the cause of reduced renal phosphate
transport in the late posttransplant period. PTH
levels are generally elevated in this population
despite normocalcemia and adequate homograft
function. The high PTH levels may be attributed to
incomplete involution of hyperplastic glands pro-
duced by renal failure prior to transplantation or to
the renal insufficiency that remains following suc-
cessful transplantation when the estimated GFR is
between 70 and 80 ml/min [51.
We have observed some patients who were hypo-
phosphatemic in the late posttransplant period with
good functioning grafts and normal PTH levels. The
pathogenesis of hypophosphatemia in this group of
patients is unclear. The present study was designed
to assess the role of multiple factors controlling
renal phosphate handling in the late posttransplant
period. The factors assessed included PTH, ne-
phrectomy, and corticosteroid ingestion. Our re-
sults reveal a group of hypophosphatemic trans-
plant recipients who fail to decrease phosphate
excretion when PTH is suppressed by calcium
infusion. We suggest that this specific, tubular
transport defect for phosphorus and the effects of
nephrectomy are important controlling factors in
renal phosphate homeostasis in the late posttrans-
plant period.
Methods
Patient groups. We evaluated 73 stable (7 months
to 14 years posttransplant) renal transplant patients
who were recipients from both living related donors
and cadaver donors. When the evaluation required
hospitalization, patients were admitted to the Clini-
cal Research Center of Washington University.
None were ingesting phosphate binders or antacids.
During the evaluation of renal phosphate handling,
23 patients were hypophosphatemic. Of these pa-
tients, ii were studied further in the hospital setting
by phosphate titration studies and/or calcium infu-
sions to suppress the effect of PTH. The hypophos-
phatemic patients did not differ in age, types of
renal disease, or dietary habits from the normo-
phosphatemic patients. None of the patients exhib-
ited significant myopathy. Also, none had signifi-
cant pretranspiant urinary volumes.
Study protocol. From all patients, we collected
serum samples to measure PTH levels and creati-
nine clearances and two 2-hour urine samples to
calculate the tubular reabsorption of phosphate
(Tm0). These collections were made the morning
of their visit to the outpatient clinic after they had
fasted. The renal threshold for phosphate (Tm04/
GFR) was determined by the nomogram of Walton
and Bijvoet [61, and GFR was determined by the
creatinine clearance.
From hospitalized patients, we obtained 24-hour
urine samples to determine creatinine, calcium,
magnesium, phosphate, sodium, potassium, pro-
tein, glucose, uric acid, and alpha amino nitrogen
excretion rates. Freshly voided morning urine sam-
ples were collected under mineral oil to determine
pH, Pco2, and bicarbonate concentration. An isoca-
loric diet containing the patient's usual intake of
sodium and phosphorus, as assessed by diet his-
tory, and 1 g of calcium were prescribed. The 11
hypophosphatemic patients who were hospitalized
had phosphate intakes ranging from 700 to 1100 mgI
day while in the hopsital.
Phosphate titration studies. Patients were al-
lowed 2 days of in-hospital stabilization. On the 3rd
hospital day, phosphate titration studies were per-
formed with i.v. infusions of 2.5% dextrose contain-
ing increasing concentrations of neutral sodium
phosphate (rate of infusion, 7 ml/min). Inulin was
added to the infusion to measure GFR. Before the
institution of i.v. fluids, each patient received a 15-
mi/kg oral water load over 30 mm. After a 30-mm
equilibration period, three 30-mm clearance periods
were allowed in the fasting state, followed by three
30-mm clearance periods at each increment of phos-
phate loading (4, 8, and 12 mg/kglhr). During each
period, clearances of inulin, creatinine, and phos-
phorus were determined. At 5, 15, and 25 mm
during each clearance period, three venous blood
samples were drawn and pooled to obtain average
values for that period. During the phosphate titra-
tion study, serum samples were drawn during fast-
ing and during each increment of phosphate loading
to obtain PTH levels. Ionized and total serum
calcium concentrations were also measured during
the entire procedure. Urinary calcium was also
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Fig. 1. Relationship between renal phosphate threshold
(TM04/GFR) determined by Bjvoet nomogram and formal
phosphate titration in 9 transplant patients and 2 normal sub-
jects.
followed during the phosphate titration. The titra-
tion was discontinued when the patient's serum
phosphate concentration exceeded 8 to 12 mg/dl.
Calcium infusion studies. After I day of stabiliza-
tion following the phosphate titration studies, cal-
cium gluceptate infusion studies were performed.
Calcium infusion involved a 24-hour control day,
followed by a 24-hour infusion of calcium glucep-
tate to maintain a serum calcium concentration of
12 to 13 mg/dl. Urine collections were divided into
6-hour periods (8 A.M. to 2 P.M., 2 P.M. to 8 P.M., 8
P.M. to 2 A.M., 2A.M. to 8 A.M.) for both control and
experimental days. Urine concentrations of cal-
cium, magnesium, phosphate, sodium, potassium,
and creatinine were determined in each period.
Venous blood samples were obtained for PTH,
creatinine, calcium, magnesium, sodium, potas-
sium, and phosphate at 0, 6, 12, 18, and 24 hours of
the control and experimental days. The 0- and 24-
hour specimens were obtained in the fasted state.
Chemical determinations. Inulin clearances (Ar-
nar-Stone) were measured by the Anthrone method
[7]. Sodium and potassium concentrations were
determined by flame spectrophotometry. Creati-
nine and phosphate concentrations were measured
by methods adapted for the Technicon autoana-
lyzer. Calcium and magnesium concentrations were
determined by atomic absorption spectrophotome-
try. Ionized calcium concentrations were deter-
mined by an Orion flow-through electrode (Orion
Research, Cambridge, Massachusetts). Immunore-
active PTH was measured with a C-terminal anti-
body [8). Normal PTH levels for our laboratory
with this antiserum are 2 to 10 p1/Eq/mi.
Calculations. Clearances were calculated by
standard formulae. Titration data was calculated by
both creatinine and inulin clearance values to obtain
the filtered load of phosphate. Student's t test was
used to assess differences between groups of pa-
tients.
Results
Figure 1 shows the correlation between Tm04/
GFR in nine transplant patients and two normal
subjects, as determined by nomogram [6] and com-
pared with that determined by actual phosphate
titration. The high degree of correlation indicated
that the Tm0/GFR determined by the nomogram
was an accurate representation of the renal phos-
phate threshold determined by our titration studies.
Table I shows the data relevant to the renal han-
dling of phosphorus in 73 transplant recipients
followed in the transplant clinic. The hypophospha-
temic transplant recipients exhibited higher levels
of GFR, similar levels of TR, and lower levels of
Tm0/GFR, than did the other transplant recipi-
ents. Transplant recipients as a group had lower
GFR's, were hypophosphatemic, hyperparathy-
roid, and exhibited phosphaturia and low phosphate
thresholds compared with normal subjects. All
transplant recipients and normal subjects were
Table 1. Renal phosphate handling in normal subjects and transplant recipientsa
Patients Ccr
mi/mm
Ppo4
mgldl
TR04% Tmp04/GFRmg/dl
P1
il/Eq/mI
Normal (N = 7)
Transplant recipients (N = 73)
Hypophosphatemic recipients (PP04 < 2.5) (N = 23)
a Results are the mean 5EM. Abbreviations are defined: Car, creatinine clearance; P04, plasma phosphate; TR04 tubular
reabsorption of phosphorus; Tm604IGFR, renal phosphate threshold by nomogram; jpTH' plasma immunoreactive PTH.b Normal range of Pp4 is 3.0 to 5.0 mg/dl.
C P < 0.005 vs. normal.
d P < 0.05 vs. whole transplant recipient group.
• Transplant
o Normal
r 0.90
Slope = 0.97
x—inter = —0.05
5
4
3
2
4 5 6
131 8
68 4c
82 8C,d
3.7 0.1
3.0 Ole
2.1 0.lC,d
90 2
67 2c
63 7c
3.5 0.2
3.0 0.1c
1.4 O.2C,d
6±1
32 4c
30 7C
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normocalcemic, and plasma calcium did not differ
between groups.
In general, Tm04/GFR levels of the transplant
recipients were related to the levels of plasma PTH.
Patients with PTH levels that were normal or only
slightly elevated (0 to 20 pA/Eq/mI) had significantly
higher Tm04/GFR's than did patients with PTH
levels above 40 id/Eq/mI (2.5 0.2 vs. 1.7 0.1
respectively, P < 0.01). But, as can be seen in Table
1, hypophosphatemic transplant recipients exhibit
reduced Tm04IGFR's at the same PTH levels of
normophosphatemic patients. This suggested, to
us, that factors other than PTH may be playing a
role in the renal phosphate handling of the hypo-
phosphatemic recipients. Thus, 11 patients of the
hypophosphatemic group were hospitalized and
studied further.
Calcium infusion and phosphate titration in
hypophosphatemic recipients. Table 2 shows the
results of calcium infusion in the 11 hospitalized
patients. The patients were divided into two groups
depending on their response to calcium infusions.
Group 1 was comprised of 5 patients whose abso-
lute excretion of phosphorus (UV04), clearance of
phosphate (Cr04), and fractional excretion of phos-
phate (FE04) did not change during the 24 hours of
calcium infusion. Group 2 was comprised of 6
patients whose UV,04, Cr04, and FEB04 were signifi-
cantly reduced during the 24 hours of calcium
infusion. As can be seen in Table 2, the effects of
calcium infusion on plasma calcium concentrations
was comparable in both groups and significantly
elevated to a mean level of 12.5 mg/dl. The plasma
phosphorus concentrations portrayed in Table 2
represent the fasting levels obtained during the 24
hours prior to (control; C) and the 24 hours of
calcium infusion (experimental; E). The plasma
phosphate concentrations listed in Table 2 are sig-
nificantly higher than the hypophosphatemic levels
(all < 2.5) exhibited as an outpatient in the fasting
state. It is possible that the phosphate titration prior
to the calcium infusion study may have contributed
to the elevation of fasting plasma phosphate con-
centrations by partially correcting a depletion state,
but overall, why the plasma phosphate consistently
increased following hospitalization is not known.
This observation is similar to the experience of Pak
et al 1191, who also did not have an adequate explana-
tion for the phenomenon. The plasma phosphate
levels of the two groups were not different during
the control day prior to calcium infusion. They were
elevated to a greater extent (P < 0.001) during
calcium infusion in group 2 patients. Plasma PTH
levels were significantly higher during the control
day in group 2 as compared to group I patients.
PTH levels were decreased during the calcium
infusion to the same extent in both patient groups.
The fact that the fall in plasma PTH levels was
associated with an increase in plasma phosphorus
and Tm04/GFR in both groups of patients indicates
a reduction in the activity of PTH on phosphate
handling. But despite the increase in the renal
phosphate threshold, the excretion of phosphate,
the phosphate clearance, and the fractional excre-
tion of phosphate were not affected in group I
patients. Although it was increased, the Tm04/GFR
was also not corrected to normal in group 1 pa-
tients. This indicates a residual defect in the trans-
port of phosphorus in the patients in group 1.
Patients in group 2 had a larger increase in their
plasma phosphate concentrations and Tm04/GFR
than did patients in group I during the calcium
infusion (2.2 to 4.3 and 2.2 to 2.5 mg/dl, respective-
ly). The correction of the Tm04/GFR to normal
levels was reflected by the reduction in UV,04, Cr04,
and FEB04 in these patients, indicating a correction
of the phosphaturia of these patients. The creatinine
clearances of the group I patients were significantly
higher than the creatinine clearances of group 2
patients. But, 3 of the group 2 patients (patients 1,
2, and 3) exhibited creatinine clearances compara-
ble to the creatinine clearances in group I patients.
These patients also exhibited a much greater in-
crease in Tm04/GFR and a reduction in U
and FEB04 during calcium infusion. Thus,
differences in creatinine clearance do not explain
the observed differences in response to calcium
infusion between the two patient groups.
Urinary cyclic AMP excretion rates were deter-
mined in 5 of the 11 hypophosphatemic recipients
during their calcium infusion studies. The results
(Table 3) indicate upper limits of normal [101 to
slightly elevated basal excretion rates of cyclic
AMP in both nonresponders and responders to
calcium infusion. Because the PTH levels were
lower in the two nonresponding patients studied,
the similar cyclic AMP excretion rates in the two
groups may indicate a hyperresponsiveness to PTH
in the group 1 patients. During calcium infusion,
cyclic AMP excretion rates were suppressed to
similar degrees in both groups but not normally
[111. The suppression of cyclic AMP excretion seen
in group 2 was related to decreased phosphate
excretion as shown in Table 2. But, the patients in
group I exhibited decrements in PTH secretion and
cyclic AMP excretion similar to group 2 in response
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Table 2. Effects of calcium infusion on renal phosphate handling by hypophosphatemic transplant recipientsa
a Abbreviations not defined in Table I are:
fractional excretion of phosphate.
'Ca' plasma calcium; UV04, urinary phosphate; Cp04, clearance of phosphate; FE04,
to calcium infusion, but failed to reduce phosphate
excretion rates and had smaller increments in plas-
ma phosphate and Tm04/GFR. Thus, these patients
were resistant to the effects of calcium infusion and
PTH suppression on phosphate excretion.
There was no evidence for tubular dysfunctions
in group 1 or 2 patients other than the observed
defect in phosphate transport. The patients were
not glycosuric, uricosuric, or aminoaciduric. The
serum potassium concentration was normal in all
patients. Hypercalciuria was not seen in any pa-
tient. Additionally, the urine volume per GFR (VI
GFR) determined during the water diuresis prior to
instituting phosphate titration was not different be-
tween the two groups and was normal (Table 4).
None of the hospitalized patients exhibited a sys-
temic acidosis. Their urinary pH's were normal and
their net acid excretion levels were normal. The
patients were also able to respond to ammonium
chloride loading by maximal acidification of the
urine.
Phosphate titration data of 9 of the 11 hypophos-
phatemic patients studied by calcium infusions are
shown in Table 5 and 6. In a previous study of renal
function in transplant patients, a marked discrepan-
cy between inulin and creatinine clearances as
determinants of GFR was noted [121. The data in
Table 5, based on creatinjne clearance, were also
Table 3. Cyclic 35' adenosine monophosphate excretion by hypophosphatemic transplant recipients during control and calcium
infusion (Exp.)
Urinary cyclic AMP PTH
nmoles/dl p.1/Eq/mi
Percent suppression by calcium Control Exp.
F 5.5
Group
4.1 25 7
4 M 4.6 3.5 22
Group 2
8
6 M 3.4 2.1 38 23 19
8 F 4.4 3.4 23 18 10
II M 5.8 3.9 33 47 25
Patient
no.
"Ca
mg/dl
Control Exp.
Pp0
mg/al
PTH
p.1/Eq/mi
Control Exp.
Cr
mi/mm
Control Exp.Control Exp.
P < 0.001
1
2
3
4
5
9.2
9.6
9.5
9.8
9.3
11.4
13.1
12.4
12.8
12.9
2.7
2.6
2.6
3.0
3.2
Group I
3.0
3.6
3.0
3.4
3.6
13
15
7
8
13
6
3
3
3
7
III
79
93
90
94
89
75
82
97
86
Mean 9.5 12.5 2.8 3.3
0.010
11 4 93 86
6
7
8
9
10
11
9.8
9.2
9.5
9.5
10.1
10.1
12.3
11.2
13.5
12.8
12.7
12.7
3.0
3.0
3.2
3.4
2.9
2.7
Group 2
5.3
4.1
4.4
4.9
5.3
4.1
23
14
18
27
21
47
19
7
10
13
6
25
89
72
71
60
49
54
97
75
78
51
51
59
Mean 9.7 12.5 3.0 4.7 25 13 66 69
0.01 NS
P <0.001
Group 1 vs. 2
< 0.001
NS < 0.001
< 0.01
< 0.05 < 0.05 < 0.01
NS
Patient no. Sex Control Exp.
determined by using inulin clearance as the marker
of GFR (Table 6). Again, no differences in CrC,
or FENa were observed between the group 1 and
group 2 patients to explain the observed low Tm04/
GFR in the group I patients. Both groups respond-
ed to phosphate infusion with increased PTH secre-
tion. PTH levels before infusion were 28 12 and
12 2 pJIEq/ml in the responder and nonresponder
groups, respectively. After phosphate infusion with
P,04 of 8 mg/dl, PTH levels increased to 58 10 and
25 4 jil/Eq/ml, respectively. Ionized calcium
levels decreased markedly at the end of the infusion
as expected (from 5.1 0.1 to 4.3 0.15 mg/dl).
Effects of nephrectomy on phosphaturia post-
transplantation. Previous investigations 1131 have
suggested that the phosphaturia that develops post-
nephrectomy in renal transplant donors is out of
proportion to the increase in the single kidney GFR.
Thus, we evaluated the relationship of Tm04IGFR
as determined by nomogram in donors prior to
nephrectomy, in 9 donors postnephrectomy and in
the paired transplant recipients (Table 7). The
Tm04IGFR was decreased significantly in donors
postnephrectomy when compared with normal sub-
jects. The Tm04/GFR in paired recipients was
decreased significantly as compared with donors
postnephrectomy. In Pabico's study [131, PTH lev-
els were normal in their transplant donors, and they
were the same before and after nephrectomy, thus
suggesting an effect of uninephrectomy independent
of PTH. In our patients, the PTH levels in the
donors and the recipient group were comparable
Table 4. The urine volume per GFR (V/GFR) in normal subjects, hypophosphatemic transplant recipients, and normophosphatemic
transplant recipients during water loadinga
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Table 2. (Continued)
UVp04
mg/day
Cp04
mi/mm
FEB04
%
Tmp04IGFR
mgldl
Control Exp. Control Exp.
NS
19.2
24.5
32.8
31.2
19.0
Group I
Group 2
Control Exp. Control Exp.
828
930
1128
1262
523
745
1034
1234
1752
621
21.2
19.3
30.6
28.1
17.9
18.5
17.5
26.9
27.1
19.4
924 1077 23.0
1092
1054
770
686
796
1184
1021
471
666
609
491
886
24.4
18.6
14.2
13.5
29.4
26.2
27.3
25.9
20.1
22.7
14.5
48.0
930 691
90
21.1 26.4
22.0
2.0
NS
25.0
3.0
NS
20.7
23.2
32.9
28.0
22.6
2.2
2.0
1.8
2.1
2.6
2.4
2.8
2.1
2.5
2.8
25.0 2.2 2.5
17.0
9.9
15.9
17.2
8.3
22.8
2.1
2.2
2.5
2.6
2.5
1.4
4.4
4.2
3.8
4.1
5.5
3.2
15.2
2.2 +
2.2
0.2
4.3
0.3
NS < 0.005 < 0.01 NS < 0.005
16.5
7.4
12.4
8.8
16.1
13.4
12.4
1.5
< 0.05 < 0.01 < 0.02
< 0.025
< 0.001
V
Patients mi/mm
Normal (N = 6) 12.4
1.2
Hypophosphatemic recipients (N — 9) 8.8
0.7
Normophosphatemic recipients (N — 8) 10.5
3.8
a Results are the means SEM. Abbreviation not defined in Table I is V, urine volume.
Cr
oil/mm
129
87
85
10
V/Cc X 100
mild! GFR
9.8
1.1
9.8
0.7
12.3
2.2
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Table 5. Relationship of creatinine clearance and fractional
excretion of sodium to renal phosphate threshold in nonre-
sponders (group I) and responders (group 2) to calcium infusiona
Group I Group 2
NS
C1, mI/mm 689
FEN,% 1.3
.6
Tm04/GFR1', mg/dI 2.4
.3
0.8
0.4
NS
2.4
and were only slightly higher in donors postne-
phrectomy when compared with levels prenephrec-
tomy. Thus, the PTH independent effects of unine-
phrectomy on phosphate transport seen in the do-
nors may also be seen in transplant recipients. Yet
there remains phosphaturia not explained by this
phenomenon as shown in Table 7.
Role of corticosteroids on phosphaturia post-
transplantation. To evaluate the effects of steroid
administration, we gave normal subjects 20 mg of
Table 8. Effect of prednisone on plasma phosphate, PTH
levels, and renal phosphate threshold in 4 normal subjectsa
During prednisone therapy 4 weeks later
P,04 2.90
0.10
2.98
0.16
NS
PTH 4.0
0.4
6.0
1.0
NS
Tmp04/GFRb, mgldl 3.2
0.1
3.1
0.2
NS
a Results are the means SEM. Abbreviations are defined in
Table I.
b GFR was determined by the clearance of creatinine.
Discussion
Several investigators have noted marked phos-
phaturia after successful renal transplantation [1—3,
14, 15] both acutely (1 to 2 weeks after transplanta-
tion) U, 121 and chronically (over 6 months after
transplantation) [2, 3, 15]. Furthermore, this associ-
ation has been noted in both cadaveric [3] and living
related transplant recipients [14, 151, and in the
living related donors after transplantation [14]. The
pathogenesis of the posttransplant phosphaturia is
unclear. The effect of PTH may be due to high
hormone levels from incomplete involution of pre-
viously hyperplastic parathyroid glands or autono-
mous (tertiary) hyperparathyroidism [14]. Alterna-
tively, increased renal tubular sensitivity to normal
levels of circulating PTH [31 or unrelated factors
Table 7. Plasma phosphate concentration and renal phosphate threshold in living related transplant donors and paired recipientsa
Pp04, mg/dI
Tmp04/GFR, ingidi
Donors prior to NPX
3.4
0.1
3.1
0.1
Donors after NPX
3.2
0.1
2.7c
0.1
Paired recipientsb
2.8c, d
0.3
2.2c, d
0.2
a Results are the means SEM. Abbreviation not defined in Table 1 is NPX, nephrectomy.
b N = 9 pairs.
P < 0.05, compared with donors prior to NPX.
d p < 0.05, compared with donors after NPX.
CC, mI/mm 94
FEN,
79
0.8
0.2
Tmp04/GFRb, mgldl 2.30.3
NS
2.4
0.1
a Results are the means SEM. Abbreviations are defined in
Tables 1 and 2.
b By titration
Table 6. Relationship of inulin clearance and fractional
excretion of sodium to renal phosphate threshold in
nonresponders (group 1) and responders (group 2) to calcium
infusiona
Group 1
prednisone daily for 2 weeks and studied them
during a phosphate titration on the last day of
prednisone administration and 4 weeks after the
medication was discontinued. Table 8 demonstrates
Group 2 no significant differences in P04, Tmp04IGFR, or
56 PTH in subjects on or off steroids. Although these
NS
8 data do not rule out an effect of long-term steroid
11 administration in the phosphaturia of hypophospha-
.2 temic renal transplant recipients, the data obtained
NS fail to support this hypothesis.
.1
NS
a Results are the means SEM. Abbreviations are defined in
Tables 1 and 2.
b By titration
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such as immunosuppressive medication [31 have
been proposed to account for the phosphaturia.
The list of potential factors that control phos-
phate homeostasis, its distribution between extra-
cellular and intracellular compartments, and its
urinary excretion is large. These factors include
dietary phosphate [161, calcium [17], ECF volume
status [18], acid-base balance [19, 20], osmotic
diuresis [211, drugs, that is, diuretics [221, steroids
[231, glucose loading, and glycosuria [21], and nu-
merous hormones. PTH is known to play the major
role in controlling day-to-day phosphate excretion
[24, 25]. Other hormones such as insulin [26],
epinephrine [27], growth hormone [28], and vitamin
D and its metabolites [29, 301 mayalso play a role in
determining serum phosphate concentrations and
urinary excretion. Glorieux and Scriver [31, 321
have suggested that renal phosphate transport is
modulated by at least two systems: (1) a PTH-
sensitive system that is responsible for the largest
portion of phosphate reabsorbed by the kidney, and
(2) a calcium-modulated transport system that is
responsible for one third of phosphate reabsorption.
These authors demonstrated that in x-linked hypo-
phosphatemic rickets, phosphate transport could
not be further influenced by endogenous or exoge-
nous PTH, but normal tubular transport of phos-
phate could be temporarily restored by calcium ion,
and by ia(OH)2D3 [32]. Normal responsiveness to
the inhibitory action of PTH on phosphate transport
could also be restored under the influence of cal-
cium. Cowgill has demonstrated an intrinsic defect
in renal tubular phosphate transport that is indepen-
dent of PTH in the mouse with familial hypophos-
phatemic rickets [331. Furthermore, a PTH inde-
pendent, calcium-modulated phosphate transport
system has been shown to exist in the dog [34] and
the rat [35].
Our data in renal transplant recipients studied in
the late posttransplant period revealed the frequent
finding of hypophosphatemia, a low tubular reab-
sorption of phosphorus relative to serum phosphate
concentrations, a decreased Tm04IGFR, and gener-
ally mild elevations of PTH. PTH levels appeared
lower than would be expected to account for de-
creased phosphate reabsorption because normo-
phosphatemic recipients had generally similar PTH
levels. More detailed investigation of 11 hypophos-
phatemic recipients revealed two patterns of re-
sponse to PTH suppression by calcium infusion. A
group of 5 of the 11 patients studied demonstrated a
defect in renal phosphate handling characterized by
an abnormally low renal phosphate threshold that
persisted even after the levels of PTH were de-
creased to normal and in the presence of marked
increases in serum calcium levels (12 to 13 mg!dl). A
second group of equally hypophosphatemic recipi-
ents, who also exhibited the same levels of Tm04!
GFR in the control setting, responded to calcium
infusion and PTH suppression by an increase in
their phosphate reabsorption, an increase in renal
phosphate threshold to normal, and a greater in-
crease in the plasma phosphorus than the patients
who failed to correct during the calcium infusion.
These data may indicate a defect in renal phosphate
handling independent of PTH and calcium in some
hypophosphatemic transplant recipients.
Another possible explanation for the presence of
hypophosphatemia and decreased phosphate reab-
sorption in the presence of relatively normal PTH
levels is a hyperresponsiveness to the action of
PTH. Our data on urinary cyclic AMP excretion
indicated that 2 of the patients who did not respond
to calcium infusion with a decrease in phosphate
excretion exhibited levels of cyclic AMP excretion
similar to the patients who responded. Because the
PTH levels of the 2 group-I patients were lower
than the 3 group-2 patients, this may indicate a
hyperresponsiveness to the action of PTH. But, the
degree of suppression in cyclic AMP excretion
induced by the calcium infusion was similar in both
group-i and group-2 patients. The suppression of
cyclic AMP excretion in the group-2 patients was
associated with an increase in phosphate reabsorp-
tion. Thus, hyperresponsiveness to the action of
PTH alone can not be used to explain the failure of
group-i patients to respond to calcium infusion by
reducing the phosphate excretion. The group-i pa-
tients would not only have to be hyperresponsive
but also resistant to the suppressive effects of
calcium for PTH to be construed as the controlling
factor in the decreased phosphate reabsorption ex-
hibited by the group-i patients. More extensive
data on the relationship between urinary cyclic
AMP excretion, PTH levels, and phosphate excre-
tion in this group of patients is indicated. There is
some suggestion in the literature that corticoste-
roids might explain a hyperresponsive state to nor-
mal PTH levels and decreased suppressibility of the
effects of PTH in transplant recipients [23, 36, 38—
40].
The patients who responded with complete cor-
rection of decreased phosphate reabsorption during
calcium infusion did not differ from those failing to
respond in terms of diet, medications, renal sodium
handling, or acid-base status. All hospitalized pa-
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tients ingested a diet containing 1 g of calcium and
700 to 1100 mg of phosphorus, an intake compatible
with their normal diet as assessed by dietary histo-
ry. The plasma phosphorus, in the hospital, tended
to increase from the outpatient setting in both
responders and nonresponders to calcium infusion.
In addition, the calcium infusions were performed
following the phosphate titration studies, and this
tended to further increase the plasma phosphorus,
as demonstrated in Table 2. But, all of these pa-
tients were clinically hypophosphatemic, at a sig-
nificant level, as demonstrated by the redevelop-
ment of hypophosphatemia and plasma phosphate
levels (less then 2.5 mg/dl) less than 1 week follow-
ing their discharge from the hospital. In addition, 2
of 3 patients in group 1 (nonresponders to calcium
infusion) who underwent iliac crest bone biopsy,
demonstrated significant osteomalacia. This further
indicates the clinical significance of the hypophos-
phatemia in this patient group.
The data presented in this study and that of
Pabico, McKenna, and Freeman [13] suggest an
important effect of uninephrectomy on phosphate
transport. That the transplanted kidney develops
the same phosphate transport characteristics as the
remaining kidney following unilateral nephrectomy
is entirely possible. This would account partially for
the PTH-independent phosphaturia seen in our cal-
cium infusion nonresponder patients with normal
PTH levels. The role of PTH in the postuninephrec-
tomy phosphaturia was not analyzed in this study
although PTH levels were only slightly higher after
nephrectomy than control. The phosphaturia of our
calcium infusion nonresponder patients was, how-
ever, clearly PTH independent.
All the patients hospitalized in the present study
were maintained on 10 to 20 mg of prednisone per
day. Corticosteroids are known to augment phos-
phaturia when administered in short-term pharma-
cologic dosages [231. But, there are no data con-
cerning phosphaturia in patients receiving long-
term maintenance prednisone. Our evaluation of 4
normal persons receiving 20 mg of prednisone daily
for 2 weeks revealed no effects of the drug on
Tm04IGFR, PTH, P,04, or TR04. Thus, at least
under the conditions of steroid administration stud-
ied, no effect on renal phosphate handling was
observed.
Corticosteroids may also stimulate PTH secre-
tion [361 and might possibly cause a hyperrespon-
sive state to the effect of PTH, but our data in 4
normal patients revealed no change in PTH levels
before or after steroid administration and no alter-
ation in phosphate handling. Furthermore, steroids
are known to stimulate insulin secretion from the
pancreas [371 and increase circulating insulin levels,
but they also induce peripheral insulin resistance.
The net effect on phosphate transport is not known.
Corticosteroids also effect the metabolism of vita-
min D. A recent report [39] noted low levels of both
25-hydroxycholecalciferol and I ,25-dihydroxycho-
lecalciferol in posttransplant patients. No relation-
ship was observed, however, between phosphate
excretion and vitamin D metabolite levels.
In a previous communication, we noted a dis-
crepancy between the C1, and Cr in both transplant
recipients and donors [121. A relationship between
phosphate clearance and GFR would be affected by
an erroneous estimate of GFR. The discrepancy
between inulin and creatinine clearances has been
noted in other [14, 15] studies of phosphate excre-
tion within the first week after transplant. In our
patients, FEB04 during phosphate loading ap-
proached 90 to 95% when the filtered load was
calculated with the inulin clearance, vs. 50% when
creatinine was used to measure GFR. The data on
phosphate excretion presented here has been in-
dexed with both creatinine and inulin as markers of
GFR when available. Our previous study suggested
that there was an impairment to the glomerular
transit of inulin following renal transplantation and
nephrectomy. Thus, our use of creatinine clearance
to index phosphate clearance when inulin data was
not available not only seems justified, but would
also diminish the magnitude of the observed phos-
phaturia.
Summary. We have demonstrated that hypophos-
phatemia and abnormal phosphaturia are seen fre-
quently in stable renal transplant recipients with
otherwise good renal function. Some of these pa-
tients continue to excrete phosphate despite reduc-
tion of PTH levels to normal and in the face of
elevated serum calcium concentrations. Thus, they
appear to exhibit a defect of renal phosphate han-
dling independent of PTH and calcium. The possi-
bility of a hyperresponsive state to normal PTH
levels with decreased suppressibility induced by
corticosteroids requires further investigation. Our
data also suggest that the effect of nephrectomy
may account for part of the apparent PTH-indepen-
dent phosphaturia, but there remains an isolated
defect in phosphate transport in some transplant
recipients with otherwise good functioning grafts.
This defect appears to be due to a PTH-independent
mechanism or to a marked alteration in PTH re-
sponsiveness.
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